“The Resmetirom Story” Seminar with Rebecca Taub

The Journey to Development and Approval for the Treatment of MASH with Liver Fibrosis: The Resmetirom Story: a Seminar by Dr. Rebecca Taub, Founder, Director, and Senior Medical and Scientific Advisor at Madrigal Pharmaceuticals.

Steatotic liver disease (SLD), including MASH and alcohol-related liver disease are among the top reasons for cirrhosis, liver failure, hepatocellular carcinoma, and liver transplant globally. Patient-centered collaboration across clinical-, biomarker-, data-, and regulatory science, and between industry and academia, has never been more important in SLD, including MASH.

Dr. Rebecca Taub will provide expert insight into the considerable, critical, challenges faced by MASH therapeutic and biomarker developers based on her experience founding Madrigal Pharmaceuticals and guiding resmetirom (REZDIFFRA) through the Accelerated Approval process.